Mutations in RB are inactivated in prostate cancer, leading to RB–E2F complex dissociation, followed by free E2F binding to the promoter of certain E2F target genes, in turn controlling the progression of tumorigenesis. This evidence concerns the gene RB1 and prostate cancer.